Logotype for Niagen Bioscience Inc

Niagen Bioscience (NAGE) Q4 2018 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Niagen Bioscience Inc

Q4 2018 earnings summary

19 Nov, 2026

Executive summary

  • FY 2018 net sales rose 49% YoY to $31.6M; TRU NIAGEN sales grew 238% to $18.5M, supporting the shift toward a consumer-focused business.

  • Q4 net sales increased 20% YoY to $9.1M; TRU NIAGEN sales reached $6.5M, up 143% YoY and 24% QoQ.

Financial highlights

  • Q4 gross margin was 52%, up 110 bps YoY; FY gross margin was 52%, up 150 bps YoY.

  • Q4 operating loss improved to $8.2M from $8.8M YoY; net loss was $8.2M versus $8.8M, and EPS was $(0.15) versus $(0.17).

  • FY operating loss from continuing operations was $33.2M versus $16.4M; net loss was $33.3M versus $11.4M.

  • Adjusted EBITDA was $(6.0)M in Q4 and $(26.0)M for FY 2018, versus $(5.2)M and $(11.2)M, respectively, in prior-year comparisons.

Outlook and guidance

  • 2019 outlook calls for continued sales growth, continued gross-margin improvement, and selling, marketing and advertising expense roughly flat in absolute dollars and lower as a share of sales.

  • Cash-flow break-even remained targeted by Q4 2019 or early 2020, supported by higher sales and gross margins, improved marketing efficiency, and leverage of fixed overhead.

  • General and administrative expense was expected to be roughly flat in absolute dollars; legal costs were primarily driven by investments to protect intellectual property.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Niagen Bioscience